You are here: Industry Insights > cardiovascular

News List

SGLT-2 inhibitors may primarily drive growth of branded heart failure treatment market: GlobalData expresspharma
September 16, 2020
Approximately 55 per cent of type T2D patients suffer from cardiovascular disease (CVD), which often leads to further complications such as major adverse cardiac events.
WHF partners with AZ to reduce burden of CV disease pharmatimes
August 26, 2020
AstraZeneca is partnering with the World Heart Federation (WHF) to progress global action to prevent, control and reduce the burden of cardiovascular (CV) disease and its associated risks and complications.
AZ partners with RenalytixAI in chronic disease pact pharmatimes
August 24, 2020
AstraZeneca has linked with RenalytixAI to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases.
Linagliptin demonstrates cardiovascular and renal safety in Asian adults with type 2 diabetes expresspharma
July 01, 2020
In a sub-analysis of the CAROLINA cardiovascular outcome trial, linagliptin demonstrated no increased cardiovascular risk versus glimepiride in Asian adults with type 2 diabetes and high cardiovascular risk.
Merck and Pfizer’s SGLT2 inhibitor STEGLATRO meets primary endpoint in VERTIS CV trial pharmaceutical-business-review
June 18, 2020
Merck, known as MSD outside the United States and Canada, and Pfizer Inc., announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin) ...
Forxiga successful in DAPA-HF heart failure trial pharmatimes
March 31, 2020
New data from a sub-analysis of AstraZeneca’s Phase III DAPA-HF trial has shown that Forxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo.
Fast Track designation granted to chronic kidney disease treatment europeanpharmaceuticalreview
March 17, 2020
The US FDA has granted Fast Track designation to Jardiance® for the treatment of chronic kidney disease.
Adding natural extracts to medicine formulation improves hypertension drugs europeanpharmaceuticalreview
March 11, 2020
A study has demonstrated that adding certain natural extracts into hypertension drug formulation aids in supporting cardiovascular function.
Updated restrictions announced for multiple sclerosis treatment europeanpharmaceuticalreview
March 11, 2020
A revised indication, additional contraindications and strengthened monitoring requirements has been recommended for Lemtrada (alemtuzumab) following a review.
Women's blood vessels age faster than men's worldpharmanews
January 16, 2020
New research from the Smidt Heart Institute at Cedars-Sinai showed for the first time that women's blood vessels - including both large and small arteries - age at a faster rate than men's.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page